ArticleCancer medicine2026
Oncological Outcomes Following Different TACE-Based Conversion Therapies for Intermediate-Advanced Hepatocellular Carcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTranscatheter arterial chemoembolization (TACE) is widely used for intermediate-advanced hepatocellular carcinoma (HCC). The efficacy and safety of TACE combined with systemic treatments as conversion therapy for HCC remain to be explored.
methodsPatients with intermediate-advanced HCC were divided as following groups based on therapy: (1) TACE; (2) TACE combined with tyrosine kinase inhibitors (TACE+TKI); (3) TACE+TKI and immune checkpoint inhibitors (TACE+TKI+ICI); and (4) TACE combined with Bevacizumab and ICI. The progression-free survival (PFS), overall survival (OS), treatment responses, and adverse events (AEs) were evaluated.
resultsOf the enrolled 518 patients, the overall objective response rate (ORR) was 21.0% and disease control rate (DCR) was 63.7%, while the TACE+TKI+ICI group showed highest ORR (28.9%) and DCR (72.8%). 147 (28.4%) patients experienced AEs during treatments. The TACE+TKI+ICI group significantly improved survival compared to TACE (mPFS: 20.7 vs. 10.9 months, p < 0.001; mOS: 44.0 vs. 13.3 months, p < 0.001) or TACE+TKI (mPFS: 20.7 vs. 15.6 months, p = 0.011; mOS: 44.0 vs. 25.0 months, p < 0.001). Of the 117 (22.6%) patients who underwent conversion liver resection, both mPFS (p = 0.016) and mOS (p < 0.001) were significantly better than those without subsequent resection. DISCUSSION: This study demonstrated that TACE+TKI+ICI had a better ORR, manageable AEs, and superior PFS and OS compared to other TACE-based conversion therapies. Undergoing subsequent liver resection significantly enhanced long-term survival compared to non-resection counterparts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.